GlaxoSmithKline plc (GSK) Receives “Buy” Rating from Liberum Capital
Liberum Capital reiterated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report report published on Tuesday morning. Liberum Capital currently has a GBX 1,900 ($25.31) price target on the stock.
A number of other equities research analysts have also recently issued reports on GSK. Shore Capital reissued a buy rating on shares of GlaxoSmithKline plc in a research report on Wednesday, June 1st. Beaufort Securities reissued a buy rating on shares of GlaxoSmithKline plc in a research report on Friday, June 3rd. Morgan Stanley set a GBX 1,500 ($19.98) target price on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research report on Tuesday, May 31st. BNP Paribas reissued a neutral rating and issued a GBX 1,560 ($20.78) target price on shares of GlaxoSmithKline plc in a research report on Thursday, August 4th. Finally, Citigroup Inc. reissued a buy rating on shares of GlaxoSmithKline plc in a research report on Wednesday, July 27th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc currently has an average rating of Hold and a consensus target price of GBX 1,676.44 ($22.33).
GlaxoSmithKline plc (LON:GSK) opened at 1636.50 on Tuesday. GlaxoSmithKline plc has a 52 week low of GBX 1,227.50 and a 52 week high of GBX 1,716.50. The company’s market cap is GBX 79.55 billion. The stock has a 50 day moving average of GBX 1,658.43 and a 200 day moving average of GBX 1,524.87.
The company also recently announced a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Thursday, August 11th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.12%. The ex-dividend date of this dividend is Thursday, August 11th.
In related news, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.55), for a total value of £169,300 ($225,492.81). Also, insider Cartwright,Stacey purchased 461 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was bought at an average cost of GBX 1,559 ($20.76) per share, with a total value of £7,186.99 ($9,572.44).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.